An SMS Intervention to Improve Adherence to Stimulant Medications in Adults With ADHD
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 125
- Locations
- 2
- Primary Endpoint
- Adherence to Stimulants
Study Overview
Brief Summary
This study will assess the efficacy of the text messaging (SMS-based) disease management intervention to improve adherence to stimulants in adults with Attention Deficit/Hyperactivity Disorder (ADHD).
Participants in the study will receive customized text messages twice a day, every day, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and female adults 18 to 55 years
- •A diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-V) Attention Deficit Hyperactivity Disorder based on clinical assessment
- •Is starting stimulant medication or has begun treatment with stimulant medication within six months of study enrollment
- •Proficient in English
- •Has a cellular phone with text messaging capabilities and is interested in and willing to receive text messages
Exclusion Criteria
- •Serious chronic medical or psychiatric condition that, in the investigator's opinion, puts the subject at risk for taking a stimulant
- •Pregnant or nursing females
- •Investigator and his/her immediate family
- •Unwilling/unable to comply with study procedures
Outcomes
Primary Outcomes
Adherence to Stimulants
Time Frame: 9 months
Adherence will be analyzed using the timeliness of stimulant medication prescription renewals over the 9 month period.
Secondary Outcomes
No secondary outcomes reported
Investigators
Joseph Biederman, MD
Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD
Massachusetts General Hospital